According to Dizhe Pharmaceutical's announcement, the cumulative deviation value of the closing price increase of the company's stock reached 30% for three consecutive trading days from July 13 to 15, 2026, which is an abnormal fluctuation. Recently, the company signed a “license agreement” with AstraZeneca, granting it the exclusive right to develop and commercialize Schwarzer® globally. It will receive a down payment of 600 million US dollars, a maximum of 400 million US dollars in clinical development and 500 million US dollars in sales milestones, as well as royalties. The transaction still needs to be reviewed by the shareholders' meeting, and the final entry into force will have to meet the conditions and obtain relevant approval. There is uncertainty. The company reminds investors to be aware of the risks.

According to Dizhe Pharmaceutical's announcement, the cumulative deviation value of the closing price increase of the company's stock reached 30% for three consecutive trading days from July 13 to 15, 2026, which is an abnormal fluctuation. Recently, the company signed a “license agreement” with AstraZeneca, granting it the exclusive right to develop and commercialize Schwarzer® globally. It will receive a down payment of 600 million US dollars, a maximum of 400 million US dollars in clinical development and 500 million US dollars in sales milestones, as well as royalties. The transaction still needs to be reviewed by the shareholders' meeting, and the final entry into force will have to meet the conditions and obtain relevant approval. There is uncertainty. The company reminds investors to be aware of the risks.